RecruitingPhase 1NCT06983743

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Sponsor

Erasca, Inc.

Enrollment

600 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Solid Tumors

Summary

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ERAS-0015 and a drug called ERAS-0015 in combination for people with metastatic solid tumors. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGERAS-0015

ERAS-0015 Administered orally

DRUGERAS-0015 in combination

ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.